A New Take on the Antidepressants vs Psychedelics Efficacy Debate
- Hannah Barnett
- Mar 24
- 3 min read
Written by Hannah Barnett
Over the past decade, psychedelic-assisted therapy (PAT) has been increasingly framed as a breakthrough in mental health care. In clinical trials, particularly for treatment-resistant depression, it is often described as faster, deeper, and more transformative than traditional antidepressants.
But what if we haven’t actually been comparing these treatments fairly?
In a recent meta-analysis I co-authored, published in JAMA Psychiatry, we set out to explore exactly that.
The Clash Between Psychedelic Trials And Modern Trial Standards
When a clinical trial is blinded—as is the case for many antidepressant trials—participants do not know whether they’ve received the active drug or a placebo. Blinded trials are considered a foundation of robust clinical research by helping to reduce bias among participants and isolate the true effect of a treatment.
It is notoriously difficult to blind participants in a full-dose psychedelic clinical trial. When someone takes a psychedelic, they eventually realize. In blinded psychedelic trials, around 90–95% of participants correctly guess their treatment. This functional unblinding matters, because expectations can significantly influence outcomes. If you believe you’ve received a powerful, cutting-edge treatment, that belief alone is shown to influence how you feel afterwards.
A Different Comparison
The psychedelics vs antidepressants debate compare the outcome of psychedelic trials to blinded antidepressant trials. But this creates an uneven playing field, as one treatment is effectively unblinded, while the other is not.
We took a different approach by comparing psychedelic trials to open-label antidepressant trials—where all patients know the treatment they’re receiving. This enables us to more fairly compare treatments under similar conditions.
What We Found
Psychedelic therapy was not more effective than antidepressants when both were evaluated under comparable (unblinded) conditions
The difference between treatments was essentially zero
Antidepressants performed slightly better on average, though the difference was not clinically meaningful
These findings challenge the dominant narrative that psychedelics are dramatically more effective than existing treatments.
Interpreting the Findings
Psychedelic trials often report much larger effects compared to placebo than antidepressant trials. But our results suggest two key reasons for this:
Expectancy effects – knowing (or strongly suspecting) you’ve received a psychedelic may amplify improvements
Lower placebo response – people in the placebo group of psychedelic trials may feel disappointed when they realise they didn’t receive the active treatment
Together, these factors can inflate the apparent effectiveness of psychedelics in standard trial comparisons.
What This Doesn't Mean
This study does not show that psychedelics don’t work.
Both psychedelic therapy and antidepressants were associated with large improvements in depression symptoms.
What our findings do suggest is more nuanced: psychedelics may not be inherently superior to antidepressants, and some of their apparent advantage may reflect how trials are designed and experienced.
Why This Matters
It’s important that all regulatory decisions are based on robust, unbiased evidence. Incorrectly relaying the clinical superiority of a treatment can distort public expectations, influence policy prematurely, and ultimately undermine trust in the field.
Our findings highlight the need for:
better trial designs that address unblinding
more realistic comparisons with existing treatments
and a broader focus beyond symptom reduction, including quality of life and functional change
Psychedelics remain a promising area of research. But like any emerging treatment, they deserve careful, critical evaluation. Because in the long run, good science, not hype, will move the field forward and benefit those in need.
